Sudeep Pharma Q2 FY27 Share Price & Earnings Call Analysis
Part of: Nifty Microcap 250 · Nifty Total Market
- Market cap
- ₹13,666 Cr
- P/E
- 72.56
- ROE
- 25.17%
- PEG
- 1.80
- Price to sales
- 19.25
- Debt to equity
- 0.20
- 52W high / low
- ₹1,344 / ₹530
- Sales growth (5Y)
- 24.45%
- EBITDA margin
- 35.33%
- Net profit margin
- 27.14%
- Promoter holding
- 76.16%
- Sales (last year)
- ₹710 Cr
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
Guidance scorecard · Q2 FY27 call
What Sudeep Pharma's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ2 FY27 call
20–40%- NSS will have a flattish year in FY27 with no significant growth; growth expected from FY28 supported by 5 secured customer approvals.
- NSS revenue in FY28 is targeted to grow at a pace similar to Sudeep's core business growth today.
- Battery materials commercial supply expected to start by FY28 with ~15-20% utilization initially, ramping to 75% over 3-4 years.
- Specialty Ingredients expected to return to positive year-on-year growth in Q3 and Q4 FY27 driven by new customer contracts despite fortified rice program pause.
- PFN business shows strong growth with core products operating near 80% utilization; greenfield plant to start adding volumes from Q4 FY27.
2 more points from Sudeep Pharma's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
FlatSee what Sudeep Pharma said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- FY27 capex was about INR77 crores, mainly towards the Battery Materials project at Dahej and completion of the greenfield facility.
- Future capex for Battery Materials Phase 2 will be based on binding contracts expected to be signed in Q4 FY27, enabling scale-up beyond initial 100,000 tons capacity.
- Greenfield facility at Dahej has recently received approval; utilization expected to start increasing from Q3 FY27 with meaningful scale from Q4 FY27.
2 more points from Sudeep Pharma's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
See what Sudeep Pharma said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
- For the Battery Materials business (iron phosphate), the company expects to sign binding commitments in Q4 FY27, before commissioning Phase 1 in April 2027.
- Strong visibility and offtake agreements exist not only for Phase 1 capacity of 25,000 tons but also for planned expansions up to 100,000 and 200,000 tons.
- Exact volume details of binding contracts versus those under negotiation will be shared in the next quarter.
- NSS (presumably a business segment) will have a flattish year in FY27 without significant growth but expects growth supported by 5 customer approvals in FY28 and FY29.
- NSS aims for ~30% EBITDA margin in FY28 post supply chain optimization.
- The greenfield facility has just begun operations, so volumes may gradually ramp up starting Q4 FY27.
2 more points from Sudeep Pharma's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,041 Cr | 33.1 | |
| 2 | 40%+ | Up 2%+ | ₹492 Cr | 19.6 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,347 Cr | — | |
| 5 | 40%+ | Flat | ₹8,432 Cr | 32.4 | |
| 6 | 40%+ | Flat | ₹4,295 Cr | — |
Sign up free to see every company in the sector ranking and track Sudeep Pharma.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Sudeep Pharma
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Sudeep Pharma
Shareholding breakup across reporting periods.
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|
| Promoters + | 76.16% | 76.16% | 76.16% | 76.16% |
| FIIs + | 1.67% | 1.55% | 1.81% | 2.93% |
| DIIs + | 17.59% | 18.11% | 15.64% | 14.06% |
| Public + | 4.57% | 4.18% | 6.39% | 6.87% |
| No. of Shareholders | 43,599 | 36,503 | 35,695 | 40,465 |
Financials of Sudeep Pharma
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 | 197 |
| YoY Sales growth | +9% | +49% | +16% | +27% | +21% | ||||
| Expenses + | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 | 123 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 | 73 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% | 37% |
| Other Income + | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 | 6 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 3 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 | 71 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% | 27% |
| Net Profit + | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 | 52 |
| EPS in Rs | 5.80 | 2.95 | 4.54 | 3.17 | 4.71 | 4.20 | 4.33 | 3.59 | 4.56 |
Financials of Sudeep Pharma
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 710 |
| Sales growth | +75% | +59% | +25% | +7% | +9% | +28% | +27% | |
| Expenses + | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 459 |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 251 |
| OPM % | 21% | 20% | 20% | 21% | 40% | 38% | 35% | 35% |
| Other Income + | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 25 |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 17 |
| Profit before tax | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 250 |
| Tax % | 27% | 22% | 27% | 28% | 24% | 24% | 24% | |
| Net Profit + | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 189 |
| EPS in Rs | 2.15 | 3.97 | 5.97 | 7.42 | 15.86 | 14.27 | 15.31 | 16.68 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Sudeep Pharma
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 | 946 |
| Borrowings + | 20 | 31 | 84 | 83 | 78 | 140 | 150 | 189 |
| Other Liabilities + | 30 | 67 | 97 | 113 | 80 | 86 | 141 | 182 |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | 1,329 |
| Fixed Assets + | 60 | 68 | 137 | 158 | 180 | 189 | 337 | 524 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 | 54 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 | 0 |
| Other Assets + | 57 | 102 | 199 | 232 | 289 | 439 | 652 | 751 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | 1,329 |
Financials of Sudeep Pharma
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Cash from Investing Activity + | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Cash from Financing Activity + | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow | -0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 62% | 104% | 22% | 78% | 60% | 47% | 56% |
Financials of Sudeep Pharma
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days Payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash Conversion Cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working Capital Days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
| ROCE % | 36% | 36% | 33% | 49% | 36% | 28% |
Guidance history
How Sudeep Pharma's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 20–40% | Flat | Planned | — | — |
| Q1 FY27 call → | 20–40% | Flat | Planned | — | Rising |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 20–40% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Sudeep Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Divis Laboratories (Q2 FY27)
Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec
- Infinium Pharma (Q2 FY27)
3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto
- Walpar Nutrition (Q2 FY27)
3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
